Surgical Endoscopy· 2026Q1
Bariatrik Cerrahide Standart Üç Doz İntravenöz Traneksamik Asit Protokolünün Uygulanabilirliği: Bir Pilot Çalışma
Feasibility of a standardized three-dose intravenous tranexamic acid protocol in bariatric surgery: a pilot study
- 0atıf
- Q1SCImago
- 2026yıl
Kısa özet
Standartlaştırılmış üç doz intravenöz traneksamik asit (TXA) protokolü, %96,0 hasta alımı ve %100 30 günlük sonuç takibi ile rutin bariatrik cerrahide uygulanabilir bulunmuştur.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Ana noktalar
- Standartlaştırılmış üç doz intravenöz traneksamik asit (TXA) protokolü, 1077 bariatrik cerrahi hastasında başarıyla uygulanmıştır.
- Uygulanabilirlik yüksekti; %96,0 hasta alımı ve %100 30 günlük sonuç takibi tamamlanmıştır.
- TXA uygulanan hastalarda %1,46, uygulanmayanlarda ise %2,84 oranında klinik olarak anlamlı kanama meydana gelmiştir (p=0,174).
- Operasyon süresi, hastanede kalış süresi ve 30 günlük tromboembolik olaylar TXA ve TXA olmayan gruplar arasında benzerdi.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Özet (abstract)
Abstract Background Tranexamic acid (TXA) has been increasingly evaluated in bariatric surgery; however, heterogeneity remains in dosing and timing, and the feasibility of implementing a standardized multidose regimen in routine practice is not well established. This pilot study evaluated implementation of a standardized three-dose intravenous TXA protocol in metabolic bariatric surgery. Methods This prospective, sequential-period pilot study included 1077 patients undergoing sleeve gastrectomy (SG), Roux-en-Y gastric bypass, or revisional surgery during alternating 3-month TXA and non-TXA periods. The primary outcome was feasibility, assessed by recruitment, protocol adherence, and completeness of 30-day outcome ascertainment. Postoperative bleeding, operative time (OT), length of stay (LOS), and thromboembolic events were evaluated exploratorily. Bleeding was assessed using Firth penalized logistic regression under intention-to-treat (ITT) and as-treated frameworks. Results Of 1,122 patients screened, 1077 were enrolled (96.0%; 95% CI 94.7–97.1%). Overall adherence to period-assigned treatment was 94.5% (95% CI 93.0–95.8%); all patients initiating TXA completed the three-dose regimen, and 30-day outcome ascertainment was 100.0% (95% CI 99.7–100.0%). Clinically significant bleeding occurred in 1.46% of patients assigned to TXA periods vs. 2.84% assigned to non-TXA periods ( p = 0.174). In ITT analysis, TXA allocation was not significantly associated with bleeding among SG patients (OR 0.55; 95% CI 0.10–2.53; p = 0.449), whereas anastomotic procedures had higher bleeding odds than SG (OR 5.41; 95% CI 1.86–18.64; p = 0.002). No treatment-by-procedure interaction was identified ( p = 0.985). OT and LOS were similar between groups, and no 30-day thromboembolic events occurred. Conclusion Implementation of a standardized three-dose intravenous TXA protocol was feasible within routine bariatric surgical practice, with high adherence and complete outcome ascertainment. Given the low bleeding event rate observed in this pilot, adequately powered studies are needed to determine whether TXA meaningfully reduces postoperative bleeding and whether its effect differs by procedure type.
Yazarların özeti; kaynağından alınmıştır. Surgical Endoscopy, 2026 · DOI ↗
Ücretsiz hesapla devam et
Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.
Web'de ücretsiz devam etGoogle ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.
Telefonda:
Alan: Biyokimya (Tıp)
BiochemistryMedicine